# FDA Grants Accelerated Approval to Vera Therapeutics' Trutakna for IgA Nephropathy

> fda · REPORTED · 2026-07-07

On July 7, 2026, the FDA granted accelerated approval to atacicept (Trutakna) by Vera Therapeutics for adults with primary IgA nephropathy at risk of disease progression, making it one of the first dual BAFF and APRIL inhibitors to reach the US market for this rare kidney disease. The approval was noted as a significant regulatory milestone in the nephrology and rare disease space.

About Vera Therapeutics: Vera Therapeutics is a clinical-stage biopharmaceutical company developing atacicept, a fusion protein that inhibits two B-cell survival factors (BAFF and APRIL), to treat immune-mediated kidney diseases including IgA nephropathy.

- Company: Vera Therapeutics
- Sector: therapeutics
- Primary source: https://healthcarereaders.com/news/healthcare-news-july-2026-roundup

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.